Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.

Per LundkvistMaria J PereiraPetros KatsogiannosC David SjöströmEva JohnssonJan W Eriksson

Published in: Diabetes, obesity & metabolism (2017)

Dapagliflozin + exenatide dual therapy produced sustained reductions in body weight, prediabetes and SBP over 52 weeks and was well tolerated in obese adults without diabetes.

Keyphrases

body weight
type diabetes
blood pressure
glycemic control
weight loss
cardiovascular disease
adipose tissue
metabolic syndrome
obese patients
heart rate
bariatric surgery
blood glucose
stem cells
hypertensive patients
insulin resistance
skeletal muscle
mesenchymal stem cells
bone marrow
replacement therapy